Amicus Therapeutics, Inc. (FRA:AM6)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.80B |
| Revenue (ttm) | 510.28M |
| Net Income (ttm) | -11.98M |
| Shares Out | n/a |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | 23.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 209 |
| Open | 12.00 |
| Previous Close | 12.00 |
| Day's Range | 12.00 - 12.00 |
| 52-Week Range | 4.80 - 12.20 |
| Beta | n/a |
| RSI | 83.62 |
| Earnings Date | Feb 18, 2026 |
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an... [Read more]
Financial Performance
In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.
Financial numbers in USD Financial StatementsNews
Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicu...
BioMarin Pharmaceutical Inc. (BMRN) Amicus Therapeutics, Inc., - M&A Call - Slideshow
Is the Market Bullish or Bearish on Amicus Therapeutics Inc?
Amicus Therapeutics Inc's (NYSE: FOLD) short interest as a percent of float has risen 7.13% since its last report. According to exchange reported data, there are now 19.31 million shares sold short ,...
What's Going On With BioMarin Stock On Tuesday?
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for a total equity value of about $4.8 billion . "Immediately upon close, this trans...
BioMarin: Amicus Buyout Sparks My Enthusiasm
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example,...
Amicus Therapeutics (FOLD) Sees Analyst Rating Downgrade from Citigroup | FOLD Stock News
Amicus Therapeutics (FOLD) Sees Analyst Rating Downgrade from Citigroup | FOLD Stock News
BioMarin Stock Surges Nearly 20% After $4.8 Bln Amicus Acquisition News
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for about $4.8 billion ...
BioMarin (BMRN) Acquires Amicus Therapeutics in $4.8B Deal
BioMarin (BMRN) Acquires Amicus Therapeutics in $4.8B Deal
Amicus Therapeutics (FOLD) Surges Over 30% Amid Positive Market Activity
Amicus Therapeutics (FOLD) Surges Over 30% Amid Positive Market Activity
BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal
BioMarin Acquires Amicus Therapeutics in $4.8 Billion Deal
Biogen (BMRN) to Acquire Amicus Therapeutics (FOLD) for $4.8 Billion
Biogen (BMRN) to Acquire Amicus Therapeutics (FOLD) for $4.8 Billion
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
Full story available on Benzinga.com
Amicus Therapeutics (FOLD) Downgraded by Needham to 'Hold' | FOLD Stock News
Amicus Therapeutics (FOLD) Downgraded by Needham to 'Hold' | FOLD Stock News
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amicus Therapeutics, Inc. (NASDAQ: FOLD) shares are trading higher on Friday after the companies penned a merger deal. Today, BioMarin agreed to acqui...
Amicus Therapeutics (FOLD) Downgraded by Cantor Fitzgerald | FOLD Stock News
Amicus Therapeutics (FOLD) Downgraded by Cantor Fitzgerald | FOLD Stock News
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transactio...
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
Amicus Therapeutics (FOLD) Shares Surge Over 30%
Amicus Therapeutics (FOLD) Shares Surge Over 30%
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per s...
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal
BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.
BioMarin (BMRN) to Acquire Amicus Therapeutics (FOLD) in $4.8B Deal
BioMarin (BMRN) to Acquire Amicus Therapeutics (FOLD) in $4.8B Deal
BioMarin to acquire Amicus Therapeutics for $4.8 billion
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases.
Pre-Market Most Active for Dec 19, 2025 : FOLD, TQQQ, TSLL, NKE, IBIT, MSTX, NVDA, ORCL, INVH, SMR, VICI, BBAI
The NASDAQ 100 Pre-Market Indicator is up 80.38 to 25,099.75. The total Pre-Market volume is currently 89,657,766 shares traded.The following are the most active stocks for the pre-market session: Ami...